XBIO - Xenetic Biosciences Inc Stock Price, Fair Value and News

3.65USD+0.10 (+2.82%)Delayed

Market Summary

USD3.65+0.10

Delayed

2.82%

XBIO Stock Price

View Fullscreen

XBIO RSI Chart

XBIO Valuation

Market Cap

5.6M

Price/Earnings (Trailing)

-1.26

Price/Sales (Trailing)

2.3

EV/EBITDA

0.08

Price/Free Cashflow

-1.35

XBIO Price/Sales (Trailing)

XBIO Profitability

Operating Margin

93.61%

EBT Margin

-685.47%

Return on Equity

-51.55%

Return on Assets

-47.62%

Free Cashflow Yield

-74.17%

XBIO Fundamentals

XBIO Revenue

Revenue (TTM)

2.4M

Rev. Growth (Yr)

-15.69%

Rev. Growth (Qtr)

-23.98%

XBIO Earnings

Earnings (TTM)

-4.5M

Earnings Growth (Yr)

-39.53%

Earnings Growth (Qtr)

-2.02%

Breaking Down XBIO Revenue

Last 7 days

-6.4%

Last 30 days

-5.4%

Last 90 days

-5.2%

Trailing 12 Months

37.2%

How does XBIO drawdown profile look like?

XBIO Financial Health

Current Ratio

11.69

Debt/Equity

0.02

Debt/Cashflow

-19.6

XBIO Investor Care

Shares Dilution (1Y)

1.58%

Diluted EPS (TTM)

-2.91

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	2.4M	0	0	0
2023	1.9M	2.2M	2.4M	2.5M
2022	1.4M	1.5M	1.6M	1.7M
2021	571.4K	746.1K	979.4K	1.2M
2020	4.7M	3.3M	1.9M	436.9K
2019	0	0	0	6.2M
2017	4.1M	5.3M	6.4M	7.6M
2016	0	0	0	3.0M
2015	0	0	0	0
2014	0	0	0	0
2013	0	221.9K	78.4K	692.8K
2012	0	0	126.7K	210.1K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Xenetic Biosciences Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jul 19, 2019	genkin dmitry	acquired	-	-	93,390	-
Mar 14, 2018	genkin dmitry	sold	-	-	-29,452	-

Which funds bought or sold XBIO recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	Tower Research Capital LLC (TRC)	reduced	-9.31	-32.00	3,487	-%
May 15, 2024	Steward Partners Investment Advisory, LLC	unchanged	-	608	7,163	-%
May 15, 2024	MORGAN STANLEY	unchanged	-	1.00	4.00	-%
May 13, 2024	GEODE CAPITAL MANAGEMENT, LLC	unchanged	-	1,983	41,487	-%
May 13, 2024	UBS Group AG	added	908	10,541	11,593	-%
May 13, 2024	UBS Group AG	new	-	-	-	-%
May 10, 2024	WELLS FARGO & COMPANY/MN	unchanged	-	3.00	41.00	-%
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
Apr 19, 2024	JTC Employer Solutions Trustee Ltd	unchanged	-	-	10,000	-%

Are Funds Buying or Selling XBIO?

Are funds buying XBIO calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own XBIO

No. of Funds

Unveiling Xenetic Biosciences Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 18, 2024	cls therapeutics, llc	5.5%	85,000	SC 13D/A
Sep 18, 2023	cls therapeutics, llc	5.5%	85,000	SC 13D/A
Jun 15, 2023	cls therapeutics, llc	5.6%	85,000	SC 13D
Oct 21, 2022	cls therapeutics, llc	9.7%	1,475,000	SC 13G
Dec 21, 2020	intracoastal capital, llc	0.0%	0	SC 13G
Feb 14, 2020	anson funds management lp	-	0	SC 13G/A
Feb 13, 2020	altium capital management lp	0%	0	SC 13G/A
Feb 10, 2020	cvi investments, inc.	0%	0	SC 13G/A
Jan 21, 2020	empery asset management, lp	1.92%	112,745	SC 13G/A
Jan 13, 2020	sabby management, llc	4.99%	287,182	SC 13G/A

Recent SEC filings of Xenetic Biosciences Inc

View All Filings

Date Filed	Form Type	Document
May 10, 2024	8-K	Current Report
May 09, 2024	10-Q	Quarterly Report
Apr 26, 2024	10-K/A	Annual Report
Mar 22, 2024	8-K	Current Report
Mar 21, 2024	10-K	Annual Report
Mar 18, 2024	SC 13D/A	13D - Major Acquisition
Feb 12, 2024	8-K	Current Report

Peers (Alternatives to Xenetic Biosciences Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Xenetic Biosciences Inc News

Latest updates

Xenetic Biosciences Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2017Q4	2017Q3	2017Q2
Revenue	-24.0%	511	672	611	651	606	487	414	417	389	333	349	288	191	151	116	113	-	-	-	-	-
Cost Of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	97.00	59.00
Operating Expenses	-7.7%	1,779	1,928	1,758	1,849	1,521	2,050	1,262	3,104	2,009	2,207	1,725	1,415	1,560	1,371	10,620	1,095	1,288	1,252	-	-	-
S&GA Expenses	-100.0%	-	952	737	946	926	857	863	1,026	907	978	945	891	931	881	804	787	928	835	-	-	-
R&D Expenses	-3.2%	944	976	1,021	903	595	1,193	399	2,077	1,101	1,229	780	525	630	491	573	308	360	417	-	-	-
EBITDA Margin	-3.8%	-6.70*	-6.46*	-6.97*	-7.62*	-8.61*	-9.72*	-10.72*	-11.20*	-12.26*	-14.35*	-17.02*	-22.34*	-	-	-	-	-	-	-	-	-
Interest Expenses	-12.5%	73.00	84.00	92.00	126	54.00	80.00	45.00	16.00	26.00	29.00	28.00	21.00	22.00	21.00	25.00	29.00	51.00	62.00	-	-	-
Income Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-2,918	-	-	-	-	-	-
Earnings Before Taxes	-	-	-	-	-	-	-	-	-	-	-	-1,350	-	-	-	-10,478	-	-	-	-	-	-
EBT Margin	-3.9%	-6.85*	-6.60*	-7.12*	-7.77*	-8.71*	-9.82*	-10.79*	-11.27*	-12.34*	-14.44*	-17.11*	-22.46*	-	-	-	-	-	-	-	-	-
Net Income	-2.0%	-1,195	-1,171	-1,055	-1,050	-856	-1,482	-804	-2,672	-1,593	-1,841	-1,350	-1,106	-1,345	-1,200	-7,560	-953	-1,179	-1,170	-	-	-
Net Income Margin	-12.4%	-1.83*	-1.63*	-1.89*	-1.94*	-3.02*	-3.84*	-4.45*	-5.01*	-4.34*	-4.86*	-5.11*	-15.03*	-19.36*	-	-	-	-	-	-	-	-
Free Cashflow	-46.2%	-1,159	-793	-947	-1,267	-1,100	-748	-1,077	-726	-2,085	-1,456	-1,031	-724	-1,517	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-11.4%	9.00	11.00	12.00	13.00	14.00	15.00	16.00	16.00	18.00	20.00	21.00	11.00	12.00	13.00	9.00	19.00	21.00	22.00	23.00	16.00	16.00
Current Assets	-12.6%	8.00	10.00	11.00	12.00	13.00	14.00	14.00	15.00	17.00	19.00	21.00	10.00	11.00	12.00	8.00	9.00	11.00	11.00	13.00	2.00	3.00
Cash Equivalents	-12.9%	8.00	9.00	10.00	11.00	12.00	13.00	14.00	15.00	16.00	18.00	20.00	9.00	10.00	12.00	7.00	8.00	9.00	10.00	12.00	1.00	2.00
Net PPE	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	166*	757*	0.00	0.00	0.00
Goodwill	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3.00	3.00
Liabilities	-11.5%	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	4.00	4.00	4.00	5.00	5.00	5.00
Current Liabilities	-11.5%	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	2.00	1.00	2.00	2.00	2.00
Shareholder's Equity	-11.4%	9.00	10.00	11.00	12.00	13.00	14.00	15.00	15.00	17.00	18.00	20.00	10.00	11.00	12.00	8.00	15.00	16.00	17.00	18.00	10.00	12.00
Retained Earnings	-0.6%	-194	-193	-192	-191	-189	-189	-187	-186	-184	-182	-180	-179	-178	-176	-175	-168	-167	-166	-164	-155	-154
Additional Paid-In Capital	0.0%	208	208	208	208	208	208	207	207	206	206	206	194	194	194	189	189	188	188	188	171	171
Shares Outstanding	0%	2.00	2.00	2.00	2.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	5.00	-	-	-	11.00	-	-	-	17.00	-	-	-	6.00	-	-	-	5.00	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-46.2%	-1,159	-793	-949	-1,269	-1,102	-750	-1,079	-728	-2,087	-1,458	-1,033	-726	-1,519	-953	-1,012	-1,300	-1,000	-1,677	-2,416	-1,050	-1,254
Share Based Compensation	-	77.00	-	-	-	69.00	-	-	-	120	113	111	110	76.00	81.00	111	112	166	123	232	234	217
Cashflow From Investing	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2.00
Cashflow From Financing	-	-	-	-	-	-	-	-	-	-	-	-	-	-	5,427	-	-	-	1.00	13,426	509*	2,699

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

XBIO Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenue:
Royalty revenue	$ 510,817	$ 605,844
Total revenue	510,817	605,844
Operating costs and expenses:
Research and development	(944,321)	(595,276)
General and administrative	(834,910)	(925,743)
Total operating costs and expenses	(1,779,231)	(1,521,019)
Loss from operations	(1,268,414)	(915,175)
Other income:
Other income	52	4,520
Interest income, net	73,249	54,101
Total other income	73,301	58,621
Net loss	$ (1,195,113)	$ (856,554)

XBIO Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash	$ 7,823,701	$ 8,983,046
Prepaid expenses and other	552,043	603,828
Total current assets	8,375,744	9,586,874
Other assets	1,018,352	1,018,352
Total assets	9,394,096	10,605,226
Current liabilities:
Accounts payable	210,483	240,832
Accrued expenses and other current liabilities	506,011	568,753
Total current liabilities	716,494	809,585
Total liabilities	716,494	809,585
Commitments and contingencies	0	0
Stockholders' equity:
Common stock, $0.001 par value; 10,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 1,543,385 shares issued as of March 31, 2024 and December 31, 2023; 1,540,684 shares outstanding as of March 31, 2024 and December 31, 2023	1,544	1,544
Additional paid in capital	208,131,009	208,053,935
Accumulated deficit	(194,429,309)	(193,234,196)
Accumulated other comprehensive income	253,734	253,734
Treasury stock	(5,281,180)	(5,281,180)
Total stockholders' equity	8,677,602	9,795,641
Total liabilities and stockholders' equity	9,394,096	10,605,226
Series B Preferred Stock [Member]
Stockholders' equity:
Preferred stock, value	$ 1,804	$ 1,804

About Xenetic Biosciences Inc

Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the development of biologic drugs and therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. In addition, the company leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, and PJSC Pharmsynthez. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.

CEO	Mr. Jeffrey F. Eisenberg Esq.
WEBSITE	xeneticbio.com
INDUSTRY	Biotechnology
EMPLOYEES	4

Xenetic Biosciences Inc Frequently Asked Questions

What is the ticker symbol for Xenetic Biosciences Inc? What does XBIO stand for in stocks?

XBIO is the stock ticker symbol of Xenetic Biosciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Xenetic Biosciences Inc (XBIO)?

As of Fri May 17 2024, market cap of Xenetic Biosciences Inc is 5.62 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of XBIO stock?

You can check XBIO's fair value in chart for subscribers.

What is the fair value of XBIO stock?

You can check XBIO's fair value in chart for subscribers. The fair value of Xenetic Biosciences Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Xenetic Biosciences Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for XBIO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Xenetic Biosciences Inc a good stock to buy?

The fair value guage provides a quick view whether XBIO is over valued or under valued. Whether Xenetic Biosciences Inc is cheap or expensive depends on the assumptions which impact Xenetic Biosciences Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for XBIO.

What is Xenetic Biosciences Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, XBIO's PE ratio (Price to Earnings) is -1.26 and Price to Sales (PS) ratio is 2.3. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. XBIO PE ratio will change depending on the future growth rate expectations of investors.